Clinical-stage biotechnology company Cynata Therapeutics
(ASX:CYP) is excited to have a scientific paper published on the efficacy of Cymerus MSCs in a preclinical model of organ transplant rejection.
The report will be published in Stem Cell Research & Therapy.
Cymerus also limits injury to the transplanted organ.
The treatment led to an i ncrease in human TSG-6, an anti-inflammatory protein, followed by an increase in peripheral mouse regulatory T cells, which play an important role in limiting transplant rejection by establishing immune tolerance.
Shares in Cynata Therapeutics
(ASX:CYP) closed -0.93 per cent lower at $1.60 yesterday.
